Taysha Gene Therapies, Inc. (TSHA) Stock Price & Analysis
Taysha Gene Therapies, Inc. (TSHA) closed at USD 4.01 on Thursday, October 22, 2026, down 2.79% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 4.12; the Oct 22, 2026 session ranged USD 3.94–4.18 on volume of 3,105,090 shares. Market capitalization is $1.30B, with a 52-week range of USD 3.46–7.3 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TSHA.md
Key facts (TSHA)
- Last four reported quarters (through Jun 30, 2026): revenue $5.5M, net income -$150M (-2728.0% margin), free cash flow -$133M (SEC filings).
- 1 of 80 tracked superinvestors hold TSHA (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $2.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -18.9% vs S&P 500 +14.9%; 5Y -74.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -0.13, revenue estimate $618K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TSHA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $2.5M | $15.5M | $8.3M | $9.8M | $5.5M |
| Operating income | -$173M | -$162M | -$72.4M | -$91.5M | -$110M | -$153M |
| Net income | -$175M | -$166M | -$112M | -$89.3M | -$109M | -$150M |
| EPS (diluted) | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 | — |
| Free cash flow | -$132M | -$109M | -$76.9M | -$81.6M | -$93.8M | -$133M |
| Operating margin | — | -6492.7% | -468.8% | -1097.6% | -1130.6% | -2792.3% |
| Net margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% | -2728.0% |
| Revenue growth | — | — | +517.5% | -46.1% | +17.3% | — |
| Cash + short-term investments | $149M | $87.9M | $144M | $139M | $320M | — |
| Total debt | $37.2M | $38.0M | $40.5M | $43.9M | $50.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TSHA)
Superinvestors (SEC 13F-HR, Q2 2026) (TSHA)
1 of 80 tracked investors hold TSHA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.03% | $3.3M | Added +53.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (TSHA)
2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar | President and Head of R&D | 200,000 | $1.2M | 17.6% | Yes (adopted June 11, 2025) | Too little history (no open-market trades in 2024) |
| 2026-04-10 | Nagendran Sukumar | President and Head of R&D | 200,000 | $892K | 15% | Yes (adopted June 11, 2025) | Too little history (no open-market trades in 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (TSHA)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-17 | Wolfe Research | Initiated | Outperform | |
| 2026-07-21 | Goldman Sachs | Target raised | Buy | $11 → $13 |
| 2026-07-02 | Citizens | Reiterated | Market Outperform | $11 |
| 2026-06-30 | Needham | Maintained | Buy | $12 |
| 2026-06-30 | Baird | Target raised | Outperform | $12 → $15 |
Total return (dividends reinvested) (TSHA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -18.9% | -74.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -19.0% | -23.9% |
| Volatility (annualized) | 71.3% | 107.5% |
| Max drawdown | -49.7% (May 2026→Oct 2026) | -95.9% (Oct 2021→Jul 2023) |
TSHA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | ABEONA THERAPEUTICS INC. (ABEO) | “License Agreement with Abeona (Rett Syndrome)” |
| Partner | Trinity Capital Inc. (TRIN) | “We have financed our operations with $961.0 million in gross proceeds from equity financings, including from pre-IPO private placements of convertible preferred stock, our initial public offering, or the IPO, and subsequent sales of common stock in public and private securities offerings, including but not limited to our at-the-market, or ATM, offering, from our previous loan agreement with Silicon Valley Bank and…” |
| Partner | Audentes Therapeutics | “We have financed our operations with $961.0 million in gross proceeds from equity financings, including from pre-IPO private placements of convertible preferred stock, our initial public offering, or the IPO, and subsequent sales of common stock in public and private securities offerings, including but not limited to our at-the-market, or ATM, offering, from our previous loan agreement with Silicon Valley Bank and…” |
Quoted from the company's 10-K filed Mar 19, 2026.
Companies that name TSHA in their SEC reports
| Relationship to TSHA | Company | Filing | Sentence |
|---|---|---|---|
| partner | ABEONA THERAPEUTICS INC. (ABEO) | 10-K Mar 17, 2026 | “the license agreement between Abeona and UNC and the corresponding sublicense agreement between Abeona and Taysha relating to Taysha's” |
TSHA company outlook (results filed Aug 11, 2026)
- “We have also expanded our partnership with Catalent, establishing a robust commercial supply framework to support the potential launch of TSHA-102 and strong demand we expect following potential FDA approval.”
- “Looking ahead, with a strengthened balance sheet, we remain focused on executing our BLA-enabling activities and anticipate reporting topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027." Recent Corporate and TSHA-102 Program Highlights Completed Dosing in the REVEAL Pivotal Trial.”
- “The interim analysis is expected to occur after all 17 patients complete six months of post-treatment follow-up.”
- “Proceeds included full exercise of the underwriters' option to purchase additional shares; anticipated cash runway extends into the second half of 2028 and through potential BLA approval of TSHA-102.”
Quoted word-for-word from the SEC 8-K results press release.
TSHA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.12 | +2.5% | $618,180 | 4 |
| Next quarter (ends Dec 2026) | $-0.13 | $-0.11 | +17.8% | $1.3M | 4 |
| Current fiscal year (ends Dec 2026) | $-0.47 | $-0.44 | +7.7% | $1.8M | 5 |
| Next fiscal year (ends Dec 2027) | $-0.46 | $-0.44 | +4.5% | $19.7M | 4 |
TSHA options: expected move
Options price a move of about ±28.2% (±$1.13) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±6.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 89.0% | ±28.2% |
| Dec 18, 2026 | 56 | 85.6% | ±26.9% |
| Jan 15, 2027 | 84 | 105.3% | ±40.0% |
| Apr 16, 2027 | 175 | 76.6% | ±42.5% |
30-day implied volatility 89.4% vs 68.8% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 4.01 |
|---|---|
| Change | ▼ 2.79% (down) |
| Previous Close | USD 4.12 |
| Open | USD 4.07 |
| Day Range | USD 3.94 – 4.18 |
| 52-Week Range | USD 3.46 – 7.3 |
| Volume | 3,105,090 shares |
| Market Cap | $1.30B |
| Exchange | NMS |
Technical Analysis (TSHA)
Nexqual's technical model rates TSHA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.49 (neutral) |
| vs SMA50 | Below (USD 5.06) |
| MACD | -0.33 (negative) |
Earnings (TSHA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $618,180 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.11 vs est -0.1 ▼ miss |
| 2025-12-31 | USD -0.07 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.09 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (TSHA)
| Total Revenue | $5.49M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -2792.32% |
| Profit Margin | +0.00% |
| ROE | -47.05% |
| Debt / Equity | 0.15 |
| Current Ratio | 17.77 |
| Total Cash | $455.41M |
| Total Debt | $56.71M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$132.57M (-2417.0% of revenue) |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financial Health Score (TSHA)
Nexqual rates Taysha Gene Therapies, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:21 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $455M cash and investments vs $49M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$133M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -47%, ROA -23.8% |
Ownership (TSHA)
| Insider Ownership | +9.45% |
|---|---|
| Institutional Ownership | +94.27% |
| Shares Outstanding | 325.83M |
| Float | 232.62M |
| Short % of Float | +17.15% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Leadership (TSHA)
Taysha Gene Therapies, Inc. is led by Sean P. Nolan, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:21 UTC.
| CEO & Chairman | Sean P. Nolan |
|---|---|
| President, Head of Research & Development and Director | Sukumar Nagendran |
| CFO & Corporate Secretary | Kamran Alam |
| Director of Corporate Communications & Investor Relations | Hayleigh Collins |
| Chief Scientific Advisor of UT Southwestern Gene Therapy Program | Steven Gray |
Major Backers & Investors (TSHA)
Notable institutional backers of Taysha Gene Therapies, Inc. include Avoro Capital Advisors LLC, RA Capital Management, L.P., Goldman Sachs, according to Nexqual as of October 23, 2026 at 09:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 7.33% |
| RA Capital Management, L.P. | 7.23% |
| Goldman Sachs | 6.97% |
| Vestal Point Capital, LP | 5.96% |
| Morgan Stanley | 5.06% |
| RTW Investments LP | 4.16% |
| FMR, LLC | 4.09% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.35% |
| Vanguard Group | 3.83% |
| State Street | 3.51% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Taysha Gene Therapies, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- In October 2025, we announced that we finalized alignment with the FDA on the REVEAL pivotal trial protocol and Statistical Analysis Plan, or SAP, that are intended to support the planned BLA submission for TSHA-102, following the resolution of remaining clinical and statistical queries.
- We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, for example seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
- We also may rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of gene therapy that may be important for the development of our business.
Partnerships
- Research, Collaboration and License Agreement with The University of Texas Southwestern Medical Center In November 2019, we entered into a research, collaboration and license agreement, or the UT Southwestern Agreement, with The Board of Regents of the University of Texas System on behalf of The University of Texas Southwestern Medical Center, or UT Southwestern, as amended in April 2020.
- In close collaboration with the United States Food and Drug Administration, or FDA, we designed the TSHA-102 pivotal program so that efficacy data from the REVEAL pivotal trial in participants aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE trial to support the potential for a broad label for TSHA-102.
Legal & Regulatory Risks (Item 1A, quoted)
- Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance.
- Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
- We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt